SEC Form 4 · accession 0001179110-18-003856
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
James DArecca
Officer — Chief Accounting Officer
Period of report
Mar 7, 2018
Accepted (ET)
Mar 8, 2018 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1 | Mar 7, 2018 | F | 93 | $153.22 | D | 3,983 | D | |
| Ordinary Shares, par value $0.0001F2,F1 | Mar 7, 2018 | A | 1,696 | $153.22 | A | 5,679 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
- F2The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 7, 2019, twenty-five percent (25%) on March 7, 2020, twenty-five percent (25%) on March 7, 2021 and twenty-five percent (25%) on March 7, 2022.